We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $439M
1-Year Est. Return 289.78%
This Fund
S&P 500
This Quarter Est. Return
+35.32%
1 Year Est. Return
+289.78%
3 Year Est. Return
+622.25%
5 Year Est. Return
+856.34%
10 Year Est. Return
+2,866.87%
AUM
$439M
AUM Growth
+$76.4M
Cap. Flow
-$4.42M
Cap. Flow %
-1.01%
Top 10 Hldgs %
28.21%
Holding
185
New
29
Increased
50
Reduced
66
Closed
38

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$4.61M
2
ALKS icon
Alkermes
ALKS
+$4.14M
3
TNGX icon
Tango Therapeutics
TNGX
+$3.85M
4
RLMD icon
Relmada Therapeutics
RLMD
+$3.12M
5
ELVN icon
Enliven Therapeutics
ELVN
+$2.75M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$6.03M
2
NUVL
Nuvalent
NUVL
+$5.8M
3
SLNO
Soleno Therapeutics
SLNO
+$5.53M
4
SYRE icon
Spyre Therapeutics
SYRE
+$5M
5
APGE
Apogee Therapeutics
APGE
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 70.95%
2 Technology 8.26%
3 Miscellaneous 6.43%
4 Industrials 4.96%
5 Financials 2.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MA icon
101
Mastercard
MA
$507B
$1.22M 0.28%
2,384
-540
-18% -$269K
ETR icon
102
Entergy
ETR
$51.3B
$1.22M 0.28%
10,628
-2,900
-21% -$327K
KRYS icon
103
Krystal Biotech
KRYS
$10.6B
$1.21M 0.28%
3,260
+1,436
+79% +$429K
MCO icon
104
Moody's
MCO
$85.5B
$1.21M 0.28%
+2,670
New +$1.2M
AMAT icon
105
Applied Materials
AMAT
$361B
$1.19M 0.27%
+1,640
New +$757K
XEL icon
106
Xcel Energy
XEL
$47.3B
$1.19M 0.27%
14,758
+2,200
+18% +$176K
NEE icon
107
NextEra Energy
NEE
$174B
$1.17M 0.27%
13,338
+2,253
+20% +$204K
UTHR icon
108
United Therapeutics
UTHR
$20.9B
$1.14M 0.26%
2,095
+581
+38% +$327K
GLNG icon
109
Golar LNG
GLNG
$5.32B
$1.1M 0.25%
+22,100
New +$1.17M
DASH icon
110
DoorDash
DASH
$91.7B
$1.07M 0.24%
5,810
-900
-13% -$149K
IBN icon
111
ICICI Bank
IBN
$109B
$1.04M 0.24%
35,884
+8,000
+29% +$216K
IRON icon
112
Disc Medicine
IRON
$3.04B
$1.04M 0.24%
+14,219
New +$977K
APH icon
113
Amphenol
APH
$204B
$1.02M 0.23%
11,562
-8,000
-41% -$577K
U icon
114
Unity
U
$18.3B
$1M 0.23%
35,163
-27,600
-44% -$734K
FERG icon
115
Ferguson
FERG
$44.2B
$990K 0.23%
4,173
-500
-11% -$121K
TRVI icon
116
Trevi Therapeutics
TRVI
$2.46B
$989K 0.23%
53,033
-492
-0.9% -$7.16K
STM icon
117
STMicroelectronics
STM
$46.6B
$989K 0.23%
+13,200
New +$794K
SEPN
118
Septerna Inc
SEPN
$1.72B
$982K 0.22%
+29,337
New +$832K
YMM icon
119
Full Truck Alliance
YMM
$8.97B
$981K 0.22%
120,847
+43,656
+57% +$372K
BBIO icon
120
BridgeBio Pharma
BBIO
$14.6B
$980K 0.22%
13,156
-36,404
-73% -$2.55M
ARM icon
121
Arm
ARM
$269B
$957K 0.22%
+2,700
New +$718K
TPR icon
122
Tapestry
TPR
$24.4B
$951K 0.22%
+6,500
New +$931K
EDU icon
123
New Oriental
EDU
$9.47B
$943K 0.22%
20,537
+8,220
+67% +$418K
SIMO icon
124
Silicon Motion
SIMO
$8.69B
$933K 0.21%
+2,800
New +$649K
APG icon
125
APi Group
APG
$17.3B
$930K 0.21%
21,958
-4,700
-18% -$205K
3 4
5
6 7

Similar funds

OGM
OnyxPoint Global Management New York $439M AUM 52.19% 1-Year Est. Return
NCM
New Capital Management Houston, Texas $439M AUM 16.55% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $438M AUM 64.84% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
CNC
Citizens & Northern Corp Wellsboro, Pennsylvania $438M AUM 26.63% 1-Year Est. Return
TAA
Turiya Advisors Asia Hong Kong $440M AUM 152.81% 1-Year Est. Return
PMA
Prudent Man Advisors Naperville, Illinois $438M AUM 34.49% 1-Year Est. Return
FW
Fairway Wealth Independence, Ohio $437M AUM 19.74% 1-Year Est. Return

HighVista Strategies's Q2 2026 Portfolio in Review

As of Q2 2026, HighVista Strategies held 185 positions worth $439M, up 21% from $362M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies's Q2 2026 filing shows 29 new, 50 increased, 66 reduced and 38 closed positions. Its largest new stake was C4 Therapeutics: 1,348,136 shares worth $6.3M. The largest sale was Terns Pharmaceuticals, an estimated $6.03M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 67% a quarter earlier, followed by Technology and Miscellaneous.

  • HighVista Strategies's largest Q2 2026 buy was C4 Therapeutics: 1,348,136 shares worth $6.3M.
  • HighVista Strategies added most to Alkermes in Q2 2026, an estimated $4.14M increase.
  • HighVista Strategies's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $5M.
  • HighVista Strategies fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $6.03M.
  • HighVista Strategies's ten largest holdings make up 28% of its $439M portfolio in Q2 2026.
  • HighVista Strategies opened 29 new positions and closed 38 in Q2 2026.
  • HighVista Strategies's portfolio value rose 21% quarter-over-quarter to $439M.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.